CY1115001T1 - Νεα παραγωγα φαινυλιμιδαζολιου ως αναστολεις ενζυμου pde10a - Google Patents

Νεα παραγωγα φαινυλιμιδαζολιου ως αναστολεις ενζυμου pde10a

Info

Publication number
CY1115001T1
CY1115001T1 CY20141100233T CY141100233T CY1115001T1 CY 1115001 T1 CY1115001 T1 CY 1115001T1 CY 20141100233 T CY20141100233 T CY 20141100233T CY 141100233 T CY141100233 T CY 141100233T CY 1115001 T1 CY1115001 T1 CY 1115001T1
Authority
CY
Cyprus
Prior art keywords
subject
compound
provides
formula
effective amount
Prior art date
Application number
CY20141100233T
Other languages
English (en)
Inventor
Andreas Ritzén
Jan Kehler
Morten Langgård
Jacob Nielsen
John Paul Kilburn
Mohamed M Farah
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of CY1115001T1 publication Critical patent/CY1115001T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η εφεύρεση αυτή κατευθύνεται προς ενώσεις, που είναι αναστολείς ενζύμου PDE10A. Η εφεύρεση παρέχει μια φαρμακευτική σύνθεση που περιέχει μια θεραπευτικώς αποτελεσματική ποσότητα μιας ένωσης της εφεύρεσης κι έναν φαρμακευτικώς αποδεκτό φορέα. Η παρούσα εφεύρεση επίσης παρέχει μεθόδους για την παρασκευή των ενώσεων του τύπου (I). Η παρούσα εφεύρεση περαιτέρω παρέχει μια μέθοδο θεραπείας ενός ατόμου που πάσχει από μια νευροεκφυλιστική διαταραχή που περιλαμβάνει χορήγηση στο άτομο μιας θεραπευτικώς αποτελεσματικής ποσότητας μιας ένωσης του τύπου (I). Η παρούσα εφεύρεση επίσης παρέχει μια μέθοδο θεραπείας ενός ατόμου που πάσχει από εξάρτηση από φάρμακο που περιλαμβάνει χορήγηση στο άτομο μιας θεραπευτικώς αποτελεσματικής ποσότητας μιας ένωσης του τύπου (I). Η παρούσα εφεύρεση επίσης παρέχει μια μέθοδο θεραπείας ενός ατόμου που πάσχει από ψυχιατρική διαταραχή που περιλαμβάνει χορήγηση στο άτομο μιας θεραπευτικώς αποτελεσματικής ποσότητας μιας ένωσης του τύπου (I).
CY20141100233T 2008-06-20 2014-03-28 Νεα παραγωγα φαινυλιμιδαζολιου ως αναστολεις ενζυμου pde10a CY1115001T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200800855 2008-06-20
DKPA200900402 2009-03-24
DKPA200900519 2009-04-22
EP09765461.0A EP2318394B1 (en) 2008-06-20 2009-06-19 Novel phenylimidazole derivatives as pde10a enzyme inhibitors

Publications (1)

Publication Number Publication Date
CY1115001T1 true CY1115001T1 (el) 2016-12-14

Family

ID=40902594

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100233T CY1115001T1 (el) 2008-06-20 2014-03-28 Νεα παραγωγα φαινυλιμιδαζολιου ως αναστολεις ενζυμου pde10a

Country Status (28)

Country Link
US (1) US8841297B2 (el)
EP (1) EP2318394B1 (el)
JP (1) JP5930714B2 (el)
KR (3) KR101703938B1 (el)
CN (2) CN102124002B (el)
AR (1) AR072199A1 (el)
AU (1) AU2009259209B2 (el)
BR (1) BRPI0915383B8 (el)
CA (1) CA2728335C (el)
CL (2) CL2010001467A1 (el)
CO (1) CO6321263A2 (el)
CY (1) CY1115001T1 (el)
DK (1) DK2318394T3 (el)
EA (2) EA018880B1 (el)
ES (1) ES2456349T3 (el)
HK (1) HK1159632A1 (el)
HR (1) HRP20140232T1 (el)
IL (1) IL209834A (el)
MX (1) MX2010014136A (el)
MY (1) MY152949A (el)
NZ (1) NZ589926A (el)
PL (1) PL2318394T3 (el)
PT (1) PT2318394E (el)
RS (2) RS53226B (el)
SI (1) SI2318394T1 (el)
TW (1) TWI501965B (el)
WO (1) WO2009152825A1 (el)
ZA (1) ZA201100109B (el)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8133897B2 (en) 2008-06-20 2012-03-13 H. Lundbeck A/S Phenylimidazole derivatives as PDE10A enzyme inhibitors
UA102693C2 (ru) 2008-06-20 2013-08-12 Х. Луннбек А/С Производные фенилимидазола как ингибиторы фермента pde10a
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
TWI481607B (zh) * 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
WO2011112828A1 (en) 2010-03-12 2011-09-15 Omeros Corporation Pde10 inhibitors and related compositions and methods
US8410117B2 (en) * 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
CN103038229B (zh) 2010-05-26 2016-05-11 桑诺维恩药品公司 杂芳基化合物及其使用方法
TW201215607A (en) 2010-07-02 2012-04-16 Lundbeck & Co As H Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor
TW201206935A (en) 2010-07-16 2012-02-16 Lundbeck & Co As H Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor
JP5760085B2 (ja) * 2010-08-04 2015-08-05 武田薬品工業株式会社 縮合複素環化合物
US8883788B2 (en) 2010-08-04 2014-11-11 Takeda Pharmaceutical Company Limited Fused heterocyclic ring compound
HUE025511T2 (en) * 2010-11-10 2016-04-28 H Lundbeck As Radio-labeled phenylimidazole-based ligands
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
US8552045B2 (en) 2010-11-19 2013-10-08 H. Lundbeck A/S Tricyclic imidazole compounds as PDE10 inhibitors
US8349824B2 (en) * 2010-12-07 2013-01-08 Hoffmann-La Roche Inc. Triazolopyridine compounds
EP2663565B1 (en) 2011-01-11 2017-03-15 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
JP2014510055A (ja) 2011-02-18 2014-04-24 アラーガン インコーポレイテッド ホスホジエステラーゼ１０（ｐｄｅ１０ａ）阻害剤としての置換６，７−ジアルコキシ−３−イソキノリノール誘導体
WO2013005798A1 (ja) * 2011-07-06 2013-01-10 持田製薬株式会社 新規含窒素複素環誘導体
WO2013045607A1 (en) 2011-09-30 2013-04-04 H. Lundbeck A/S Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors
WO2013050527A1 (en) 2011-10-05 2013-04-11 H. Lundbeck A/S Quinazoline derivatives as pde10a enzyme inhibitors
AR089361A1 (es) * 2011-12-21 2014-08-20 Lundbeck & Co As H Derivados de quinolina como inhibidores de la enzima pde10a
WO2013127817A1 (en) 2012-02-27 2013-09-06 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
WO2013178572A1 (en) * 2012-05-30 2013-12-05 F. Hoffmann-La Roche Ag Triazolo compounds as pde10 inhibitors
WO2013192273A1 (en) 2012-06-19 2013-12-27 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
EP2935271B1 (en) 2012-12-21 2017-10-25 Bristol-Myers Squibb Company Novel substituted imidazoles as casein kinase 1 / inhibitors
KR102169426B1 (ko) * 2013-02-27 2020-10-23 모찌다 세이야쿠 가부시끼가이샤 신규 피라졸 유도체
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
ES2759246T3 (es) 2014-04-23 2020-05-08 Dart Neuroscience Cayman Ltd Compuestos de[1,2,4]triazolo[1,5-a]pirimidinilo-7-il sustituidos como inhibidores de PDE2
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
PL408251A1 (pl) * 2014-05-19 2015-11-23 Celon Pharma Spółka Z Ograniczoną Odpowiedzialnością Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A
WO2016073424A1 (en) * 2014-11-05 2016-05-12 Dart Neuroscience, Llc Substituted 5-methyl-[1, 2, 4] triazolo [1,5-a) pyrimidin-2-amine compounds as pde2 inhibitors
CA2980801A1 (en) 2015-04-24 2016-10-27 Omeros Corporation Pde10 inhibitors and related compositions and methods
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor
WO2020094591A1 (en) 2018-11-06 2020-05-14 H. Lundbeck A/S Pde10a inhibitors for treating negative symptoms and cognitive impairments in a patient suffering from schizophrenia
US20200140446A1 (en) 2018-11-06 2020-05-07 H. Lundbeck A/S 5,8-dimethyl-2-[2-(1-methyl-4-phenyl-1h-imidazol-2-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyrazine hemiadipate
BR112020013697A2 (pt) 2018-11-06 2020-12-01 H. Lundbeck A/S compostos para tratamento de sintomas negativos e comprometimentos cognitivos
CN110981813A (zh) * 2019-12-19 2020-04-10 西安近代化学研究所 一种2-氰基-5-芳基-1h-咪唑类化合物的合成方法
CN111100071A (zh) * 2019-12-19 2020-05-05 西安近代化学研究所 一种合成2-氰基-5-芳基-1h-咪唑类化合物的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036840A (en) 1972-06-07 1977-07-19 Icn Pharmaceuticals 2-Substituted-s-triazolo[1,5a]pyrimidines
DE10230605A1 (de) 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
AU2004253694A1 (en) * 2003-06-30 2005-01-13 4Sc Ag Novel pyrrolodihydroisoquinolines useful in the treatment of cancer
CA2556413A1 (en) * 2004-02-18 2005-09-09 Pfizer Products Inc. Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
AU2005221131A1 (en) 2004-03-08 2005-09-22 Wyeth Ion channel modulators
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
WO2007098169A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
JP2009541481A (ja) 2006-06-26 2009-11-26 ファイザー・プロダクツ・インク Ｐｄｅ１０阻害剤としての三環式ヘテロアリール化合物
US7897619B2 (en) 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
EP2187883A2 (en) 2007-08-10 2010-05-26 Genelabs Technologies, Inc. Nitrogen containing bicyclic chemical entities for treating viral infections
UA102693C2 (ru) 2008-06-20 2013-08-12 Х. Луннбек А/С Производные фенилимидазола как ингибиторы фермента pde10a
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
US8133897B2 (en) 2008-06-20 2012-03-13 H. Lundbeck A/S Phenylimidazole derivatives as PDE10A enzyme inhibitors

Also Published As

Publication number Publication date
ZA201100109B (en) 2012-03-28
JP5930714B2 (ja) 2016-06-08
CN102124002B (zh) 2014-06-25
ES2456349T3 (es) 2014-04-22
MX2010014136A (es) 2011-01-21
CN102482262B (zh) 2014-06-25
IL209834A0 (en) 2011-02-28
PL2318394T3 (pl) 2014-09-30
EP2318394A1 (en) 2011-05-11
EA201170061A1 (ru) 2011-08-30
NZ589926A (en) 2011-09-30
WO2009152825A1 (en) 2009-12-23
EA021410B1 (ru) 2015-06-30
CL2011003205A1 (es) 2012-06-22
BRPI0915383B8 (pt) 2021-05-25
US8841297B2 (en) 2014-09-23
EP2318394B1 (en) 2014-01-22
HRP20140232T1 (hr) 2014-04-11
BRPI0915383A2 (pt) 2015-11-03
JP2011524381A (ja) 2011-09-01
HK1159632A1 (en) 2012-08-03
PT2318394E (pt) 2014-04-03
TWI501965B (zh) 2015-10-01
MY152949A (en) 2014-12-15
KR102025487B1 (ko) 2019-09-25
AU2009259209B2 (en) 2013-08-01
CN102124002A (zh) 2011-07-13
DK2318394T3 (en) 2014-03-24
SI2318394T1 (sl) 2014-07-31
EA018880B1 (ru) 2013-11-29
CA2728335A1 (en) 2009-12-23
TW201000481A (en) 2010-01-01
KR20170134781A (ko) 2017-12-06
CA2728335C (en) 2016-05-24
RS53226B (en) 2014-08-29
RS53704B1 (en) 2015-04-30
US20120190685A1 (en) 2012-07-26
BRPI0915383B1 (pt) 2020-09-15
KR20110020845A (ko) 2011-03-03
CL2010001467A1 (es) 2011-08-05
IL209834A (en) 2014-02-27
CO6321263A2 (es) 2011-09-20
AU2009259209A1 (en) 2009-12-23
EA201270046A1 (ru) 2012-05-30
KR101703938B1 (ko) 2017-02-07
AR072199A1 (es) 2010-08-11
KR20170016523A (ko) 2017-02-13
CN102482262A (zh) 2012-05-30

Similar Documents

Publication Publication Date Title
CY1115001T1 (el) Νεα παραγωγα φαινυλιμιδαζολιου ως αναστολεις ενζυμου pde10a
CY1115843T1 (el) Ετεροαρωματικες ενωσεις φαινυλιμιδαζολιου ως αναστολεις ενζυμου pde10a
CY1115278T1 (el) Παραγωγα 2-αρυλιμιδαζολης ως αναστολεις του ενζυμου ρdε10α
UA102693C2 (ru) Производные фенилимидазола как ингибиторы фермента pde10a
EA201290517A1 (ru) Гетероароматические арилтриазольные производные в качестве ингибиторов фермента pde10a
IN2015DN02829A (el)
EA201390741A1 (ru) Производные имидазола в качестве ингибиторов фермента pde10a
PH12014501695B1 (en) Pde9 inhibitors with imidazo triazinone backbone
CY1116689T1 (el) Παραγωγα ιμιδαζολης ως αναστολεις του ενζυμου pde10a
MX336915B (es) Derivados de imidazol como inhibidores de la enzima pde10a.
TN2013000200A1 (en) Imidazole derivatives as pde 10a enzyme inhibitors